HomeNucleix Ltd

Nucleix Ltd

Publication of Non-Invasive Bladder Cancer Recurrence Detection Study Showing Best-in-Class Performance Announced by Nucleix

7/24/18: The multi-center, single-arm, prospective, double-blind clinical study was performed in five leading urology centers in Europe, on 440 patients who were recruited in their first year of follow-up. The study compared the results of Bladder EpiCheck to the current gold standard follow-up sequence (cystoscopy, cytology and pathology verification). Bladder EpiCheck demonstrated a clinically relevant and high negative predictive value (NPV), with NPV of 99.3% and sensitivity of 91.7% (both excluding patients with low-grade tumors) and specificity of 88%.